Neue Therapien in der Onkologie – Wirkweise und Nebenwirkungen

 

 Buy Article Permissions and Reprints

Publication History

Article published online:
27 October 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• Literatur

• 1 DeVita Jr VT, Chu E. A history of cancer chemotherapy. Cancer Res 2008; 68: 8643-8653 DOI: 10.1158/0008-5472.CAN-07-6611.
  CrossrefPubMedGoogle Scholar
• 2 Rosas D, Raez LE. Review of the agnostic-type treatment approach: treating cancer by mutations, not by location. Oncol Ther 2020; 8: 59-66 DOI: 10.1007/s40487-020-00114-4.
  CrossrefPubMedGoogle Scholar
• 3 Wirk B, Wingard JR, Moreb JS. Extramedullary disease in plasma cell myeloma: the iceberg phenomenon. Bone Marrow Transplant 2013; 48: 10-18 DOI: 10.1038/bmt.2012.26.
  CrossrefPubMedGoogle Scholar
• 4 Alt-Epping B, Fuxius S, Wedding U. Hrsg. Onkologie für die Palliativmedizin. 2015. DOI: 10.17875/gup2015-850
  CrossrefGoogle Scholar
• 5 Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70 DOI: 10.1016/s0092-8674(00)81683-9.
  CrossrefPubMedGoogle Scholar
• 6 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674 DOI: 10.1016/j.cell.2011.02.013.
  CrossrefPubMedGoogle Scholar
• 7 Baudino TA. Targeted cancer therapy: the next generation of cancer treatment. Curr Drug Discov Technol 2015; 12: 3-20 DOI: 10.2174/1570163812666150602144310.
  CrossrefPubMedGoogle Scholar
• 8 Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009; 9: 28-39 DOI: 10.1038/nrc2559.
  CrossrefPubMedGoogle Scholar
• 9 Kämmerer W. Interaktionen Achtung bei Tyrosinkinase-Inhibitoren. Pharmazeut Z; 2009 20.
  PubMedGoogle Scholar
• 10 Müller-Tidow CK, Brunnberg U, Berdel U. et al. Tyrosinkinasen als Ziele neuer onkologischer Therapien. Dtsch Ärztebl 2007; 104: A-1312-1319
  PubMedGoogle Scholar
• 11 Reungwetwattana T, Nakagawa K, Cho BC. et al. CNS Response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated egfr-mutated advanced non-small-cell lung cancer. J Clin Oncol 2018; 36: 3290-3297 DOI: 10.1200/JCO.2018.78.3118.
  CrossrefPubMedGoogle Scholar
• 12 Valiente M, Ahluwalia MS, Boire A. et al. The Evolving landscape of brain metastasis. Trends Cancer 2018; 4: 176-196 DOI: 10.1016/j.trecan.2018.01.003.
  CrossrefPubMedGoogle Scholar
• 13 Hurvitz SA, OʼShaughnessy J, Mason G. et al. Central Nervous system metastasis in patients with her2-positive metastatic breast cancer: patient characteristics, treatment, and survival from SystHERs. Cancer Res 2019; 25: 2433-2441 DOI: 10.1158/1078-0432.CCR-18-2366.
  CrossrefPubMedGoogle Scholar
• 14 Piper-Vallillo AJ, Sequist LV, Piotrowska Z. Emerging Treatment paradigms for egfr-mutant lung cancers progressing on osimertinib: a review. J Clin Oncol 2020; DOI: 10.1200/JCO.19.03123.
  CrossrefPubMedGoogle Scholar
• 15 Ramalingam SS, Vansteenkiste J, Planchard D. et al. Overall Survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 2020; 382: 41-50 DOI: 10.1056/NEJMoa1913662.
  CrossrefPubMedGoogle Scholar
• 16 Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol 2014; 11: 473-481 DOI: 10.1038/nrclinonc.2014.104.
  CrossrefPubMedGoogle Scholar
• 17 Park K, Yu CJ, Kim SW. et al. First-Line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION Study. JAMA Oncol 2016; 2: 305-312 DOI: 10.1001/jamaoncol.2015.4921.
  CrossrefPubMedGoogle Scholar
• 18 Vavala T, Follador A, Tiseo M. et al. BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study. Lung Cancer 2016; 95: 73-81 DOI: 10.1016/j.lungcan.2016.02.011.
  CrossrefPubMedGoogle Scholar
• 19 Weickhardt AJ, Scheier B, Burke JM. et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012; 7: 1807-1814 DOI: 10.1097/JTO.0b013e3182745948.
  CrossrefPubMedGoogle Scholar
• 20 Alt-Epping B. Was soll die Palliativmedizin im Tumorboard?. Forum 2019; 34: 331-334 DOI: 10.1007/s12312-019-0633-2.
  CrossrefPubMedGoogle Scholar
• 21 Kolb G, Bokemeyer C, Wedding U. Geriatrisches Assessment: Integration ins Tumorboard. Dtsch Ärztebl 2020; 117: A-1382/B-1182
  PubMedGoogle Scholar
• 22 Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol 2018; 19: 31-39 DOI: 10.1007/s40257-018-0384-3.
  CrossrefPubMedGoogle Scholar
• 23 Tsimberidou AM, Kurzrock R. Precision medicine: lessons learned from the SHIVA trial. Lancet Oncol 2015; 16: e579-580 DOI: 10.1016/S1470-2045(15)00397-6.
  CrossrefPubMedGoogle Scholar
• 24 Sicklick JK, Kato S, Okamura R. et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med 2019; 25: 744-750 DOI: 10.1038/s41591-019-0407-5.
  CrossrefPubMedGoogle Scholar
• 25 Nagarkar R, Patil D, Crook T. et al. Encyclopedic tumor analysis for guiding treatment of advanced, broadly refractory cancers: results from the RESILIENT trial. Oncotarget 2019; 10: 5605-5621 DOI: 10.18632/oncotarget.27188.
  CrossrefPubMedGoogle Scholar
• 26 Teleanu RI, Chircov C, Grumezescu AM. et al. Tumor Angiogenesis and anti-angiogenic strategies for cancer treatment. J Clin Med 2019; 9: 84 DOI: 10.3390/jcm9010084.
  CrossrefPubMedGoogle Scholar
• 27 Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015; 348: 56-61 DOI: 10.1126/science.aaa8172.
  CrossrefPubMedGoogle Scholar
• 28 Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res 2019; 38: 255 DOI: 10.1186/s13046-019-1259-z.
  CrossrefPubMedGoogle Scholar
• 29 Hause RJ, Pritchard CC, Shendure J. et al. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med 2016; 22: 1342-1350 DOI: 10.1038/nm.4191.
  CrossrefPubMedGoogle Scholar
• 30 Luchini C, Bibeau F, Ligtenberg MJL. et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO 2019; 30: 1232-1243 DOI: 10.1093/annonc/mdz116.
  CrossrefPubMedGoogle Scholar
• 31 Miller AM, DeAngelis LM. Reevaluation of the Frequent Use of PD-1 Checkpoint Inhibitors for Treatment of Glioblastoma. JAMA 2020; 323: 2482-2484
  CrossrefPubMedGoogle Scholar
• 32 Bedognetti D, Ceccarelli M, Galluzzi L. et al. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer 2019; 7: 131 DOI: 10.1186/s40425-019-0602-4.
  CrossrefPubMedGoogle Scholar
• 33 Heinzerling L, de Toni E, Schett G. et al. Checkpoint-Inhibitoren Diagnostik und Therapie von Nebenwirkungen. Dtsch Ärztebl 2019; 116: 119-126
  CrossrefPubMedGoogle Scholar
• 34 Chai LF, Prince E, Pillarisetty VG. et al. Challenges in assessing solid tumor responses to immunotherapy. Cancer Gene Ther 2020; 27: 528-538 DOI: 10.1038/s41417-019-0155-1.
  CrossrefPubMedGoogle Scholar
• 35 Toi Y, Sugawara S, Kawashima Y. et al. Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer Treated with Nivolumab. Oncologist 2018; 23: 1358-1365 DOI: 10.1634/theoncologist.2017-0384.
  CrossrefPubMedGoogle Scholar
• 36 Haen SP, Loffler MW, Rammensee HG. et al. Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nat Rev Clin Oncol 2020; DOI: 10.1038/s41571-020-0387-x.
  CrossrefPubMedGoogle Scholar
• 37 Rosenbaum L. Tragedy, perseverance, and chance – the story of CAR-T therapy. N Engl J Med 2017; 377: 1313-1315 DOI: 10.1056/NEJMp1711886.
  CrossrefPubMedGoogle Scholar
• 38 Urba WJ, Longo DL. Redirecting T cells. N Engl J Med 2011; 365: 754-757 DOI: 10.1056/NEJMe1106965.
  CrossrefPubMedGoogle Scholar
• 39 Buchholz CJ, Hartmann J, Schüßler-Lenz M. et al. CAR-T-Zell-Therapie: Aussichten und Risiken. Dtsch Ärztebl 2018; 115: 38-41
  PubMedGoogle Scholar
• 40 Mukherjee S. The Promise and price of cellular therapies. The New Yorker; 2019. https://www.newyorker.com/magazine/2019/07/22/the-promise-and-price-of-cellular-therapies
  Google Scholar
• 41 Repp R, Valerius T, Bargou R. Bispezifische Antikörper in der Hämatologie und Onkologie. Der Internist 2001; 42: 854-859 DOI: 10.1007/s001080170128.
  CrossrefPubMedGoogle Scholar
• 42 Przespolewski AC, Griffiths EA. BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting. Blood reviews 2020; DOI: 10.1016/j.blre.2020.100654.
  CrossrefPubMedGoogle Scholar
• 43 Le Saux O, Falandry C, Gan HK. et al. Inclusion of elderly patients in oncology clinical trials. Ann Oncol 2016; 27: 1799-1804
  CrossrefPubMedGoogle Scholar